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Influenza antigenic and genetic characterisation data 
are crucial for influenza vaccine composition decision 
making. Previously, aggregate data were reported to 
the European Centre for Disease Prevention and Control 
by European Union/European Economic Area (EU/EEA) 
countries. A system for collecting case-specific influ-
enza antigenic and genetic characterisation data was 
established for the 2013/14 influenza season. In a pilot 
study, 11 EU/EEA countries reported through the new 
mechanism. We demonstrated feasibility of reporting 
strain-based antigenic and genetic data and ca 10% 
of influenza virus-positive specimens were selected 
for further characterisation. Proportions of character-
ised virus (sub)types were similar to influenza virus 
circulation levels. The main genetic clades were rep-
resented by A/StPetersburg/27/2011(H1N1)pdm09 
and A/Texas/50/2012(H3N2). A(H1N1)pdm09 viruses 
were more prevalent in age groups (by years) < 1 (65%; 
p = 0.0111), 20–39 (50%; p = 0.0046) and 40–64 (55%; 
p = 0.00001) while A(H3N2) viruses were most preva-
lent in those ≥ 65 years (62%*; p = 0.0012). Hospitalised 
patients in the age groups 6–19 years (67%; p = 0.0494) 
and ≥ 65 years (52%; p = 0.0005) were more frequently 
infected by A/Texas/50/2012 A(H3N2)-like viruses 
compared with hospitalised cases in other age groups. 
Strain-based reporting enabled deeper understand-
ing of influenza virus circulation among hospitalised 
patients and substantially improved the reporting of 
virus characterisation data. Therefore, strain-based 
reporting of readily available data is recommended to 
all reporting countries within the EU/EEA.
Background
Influenza virological surveillance data, including 
characteristics of circulating viruses, are collected to 
describe the annual occurrence of influenza virus (sub)
types and lineages for selection of vaccine compo-
nents for the following season. Virological surveillance 
also supports epidemic and pandemic preparedness 
with detection of emerging influenza viruses. European 
Union and European Economic Area (EU/EEA) countries 
report influenza surveillance data on a weekly basis 
during influenza seasons as part of the World Health 
Organization (WHO) Global Influenza Surveillance and 
Response System (GISRS) [1] to describe the antigenic 
character and genetic makeup of circulating viruses [2]. 
Surveillance at the EU/EEA level is carried out by the 
European Influenza Surveillance Network (EISN) and 
data are collected on a weekly basis in The European 
Surveillance System (TESSy) under the coordination 
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C. Aggregate and strain-based genetic characterisations 
    of A(H1N1)pdm09 viruses
Aggr GEN A/California/7/2009 A(H1N1)pdm09
Aggr GEN A/St Petersburg/27/2011 A(H1N1)pdm09






E. Aggregate and strain-based antigenic characterisations 
    of A(H3N2) viruses
Aggr AG A/Texas/50/2012 A(H3N2)






F. Aggregate and strain-based genetic characterisations 
    of A(H3N2) viruses
Aggr GEN A/Texas/50/2012 A(H3N2)






B. Aggregate and strain-based antigenic characterisations 
     of A(H1N1)pdm09 viruses
Aggr AG A/California/7/2009 A(H1N1)pdm09
Str AG A/California/7/2009 A(H1N1)pdm09
AG: antigenic; aggr: aggregate; GEN: genetic; str: strain-based.
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Figure 2
Phylogenetic and cluster analysis of available haemagglutinin 1 sequences, strain-based reporting of antigenic and genetic 
characterisation data for influenza viruses, 11 European countries, influenza season 2013/14 (n=596)













A. Influenza A(H1)pdm09 viruses


























B. Influenza A(H3) viruses






















ERLI-Net: European Reference Laboratory Network for Human Influenza; HA: haemagglutinin; Ref: ERLI-Net reference sequences.
Maximum-likelihood analysis of HA1 subunit sequences is shown. The reported haemagglutinin sequences and ERLI-Net reference sequences 
were colour-coded according to their attributed genetic categories. Identical sequences are displayed as segmented node circles where the 
circle area and number of segments represent the number of viruses.
4 www.eurosurveillance.org
Through the sentinel and non-sentinel surveillance sys-
tems in EU/EEA countries, subsets of viruses, detected 
across the season from different geographic locations 
and from different demographic groups, are further 
characterised by the National Influenza Centres (NICs) 
for their antigenic and genetic properties, and antiviral 
susceptibility. Smaller subsets of influenza virus posi-
tive specimens and virus isolates are sent by NICs to 
a WHO Collaborating Centre for Influenza Reference 
and Research (CC), mainly the WHO CC London, United 
Kingdom, for detailed characterisation.
Historically, EU/EEA countries have reported aggre-
gate influenza virus detections by type and subtype, 
together with influenza-like illness (ILI)/acute respira-
tory infection (ARI) consultation rate data from sentinel 
primary healthcare providers to TESSy. Antigenic and 
genetic characteristics for a subset of these viruses, 
aggregated by week of sampling, have been reported 
according to predefined categories, based on reference 
viruses representing antigenic and genetic similarity 
to either vaccine viruses or known antigenic/genetic 
‘drift’ variants. Due to the aggregate format, patient 
information (e.g. age, sex, vaccination or hospitalisa-
tion status) was not collected. The majority of coun-
tries reported age group-specific ILI/ARI rates without 
being able to link them to age-specific virological data. 
In 2004, strain-based reporting of influenza antivi-
ral susceptibility with epidemiological, demographic 
and clinical information was introduced [5]. In the 
2007/08 influenza season, this new system facilitated 
rapid assessment of the spread of former seasonal 
A(H1N1) influenza viruses showing clinical resistance 
to oseltamivir due to neuraminidase (NA) H275Y amino 
acid substitution [6].
Although there have been earlier studies on sever-
ity and its association with influenza subtypes [7-10], 
there is limited evidence of risk factors for severe influ-
enza or influenza complications due to specific sub-
types and viruses [11]. To assess the disease burden 
in different patient risk groups caused by influenza 
viruses of various (sub)types with particular antigenic 
and genetic characteristics, it is crucial from the public 
health perspective to have detailed information about 
the distribution of specific viruses in different risk 
groups. This study piloted the integrated collection of 
strain-based antigenic and genetic characterisation 
data and epidemiological, demographic and clinical 
information.
The objectives were: (i) to test the feasibility of collect-
ing influenza virus strain-based antigenic and genetic 
data; and (ii) to assess the collected data and explore 
the benefits of non-aggregate strain-based reporting.
Methods
Data collection
Respiratory specimens were obtained in the par-
ticipating countries as part of their routine influenza 
surveillance activities from week 40/2013 to week 
39/2014. Sentinel general practitioners swabbed 
patients with ILI and/or another ARI, with most meeting 
the EU case definition for ILI and/or ARI [12], depending 
on the country’s choice of syndrome under surveillance 
and following the nationally agreed sampling protocol. 
Non-sentinel specimens, mainly from hospital labo-
ratories, were also included. All specimens were ana-
lysed for the presence of influenza virus, by real-time 
RT-PCR, at the local laboratory or the NIC. If specimens 
were first analysed at a local laboratory, all or a subset 
of influenza-virus-positive specimens or virus isolates 
were sent to the NIC for further analysis of subtype or 
lineage, antigenic characterisation by haemagglutina-
tion inhibition assay, and genetic characterisation by 
sequencing of haemagglutinin (HA) genes. All partici-
pating laboratories take part in regular external quality 
assessments of rapid detection, virus culture, antigenic 
and genetic characterisation and antiviral susceptibility 
analysis [13]. Within EISN, a target of characterising ca 
10% of influenza detections has been agreed, although 
depending on predominant virus (sub)type and inten-
sity of the epidemic, it is valid to characterise less than 
10%. In addition, NICs sent smaller subsets of speci-
mens and virus isolates to the WHO CC in London for 
more detailed characterisation. When selecting speci-
mens for characterisation, laboratories were expected 
to include specimens with sufficient viral load, based 
on their resources from all (sub)types, from different 
age groups, surveillance systems, geographical loca-
tions and phases of the epidemic [14].
As part of the existing reporting scheme, countries 
reported weekly aggregate virological influenza sur-
veillance and antigenic and genetic characterisation 
data to ECDC. Prefixed, coded reporting categories 
defined by WHO CC London were used for antigenic and 
genetic characteristics which included vaccine viruses 
and additional non-vaccine reference viruses with spe-
cific antigenic properties or specified HA amino acid 
substitutions and phylogenetic clade (see Table 1 for 
the categories).
In addition, for this pilot study, all EU/EEA countries 
were invited to submit antigenic and/or genetic charac-
terisation data in strain-based format. The virus name, 
e.g. A/Netherlands/2245/2013, acted as a unique 
identifier and duplicated data from national and WHO 
CC sources were merged. The epidemiological data 
included variables: age, complication diagnosis, date 
of onset, exposure to antiviral drugs, sex, hospitali-
sation, immunocompromised status, outcome, prob-
able country of infection and vaccination status. All 
data for the 2013/14 influenza season were extracted 
from TESSy on 15 January 2015. In addition, HA-gene 
sequences of viruses for which database accession 
numbers were reported were retrieved from the Global 




Proportions of influenza virus genetic clades by patient age, strain-based reporting of antigenic and genetic characterisation 
data from (A) all reported cases with age from 11 European countries (n = 1,061) and (B) hospitalised non-sentinel cases 














































A. All reported cases from 11 European countries
B. Hospitalised non-sentinel cases reported from eight European countries
A/St Petersburg/27/2011 A(H1N1)pdm09
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Distribution of genetic clades between different age groups compared by Dunn’s test with Bonferroni adjustment, p values indicated for each 
statistically significant comparison.
The 11 countries in panel A are Belgium, Finland, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Spain and Sweden.
The eight countries in panel B are Finland, Greece, Ireland, the Netherlands, Norway, Portugal, Spain and Sweden.
6 www.eurosurveillance.org
Data analysis
Feasibility of strain-based reporting was assessed 
through the pilot, looking at country-wide distribution 
among participating countries and data completeness. 
We also received comments on the feasibility of the 
reporting by questionnaire.
Detection and characterisation data were plotted by 
week of specimen collection over the influenza season 
(week 40/2013 to week 39/2014) and timing of aggre-
gate and strain-based antigenic and genetic characteri-
sations were compared between detections from both 
sentinel and non-sentinel data sources.
Nucleic acid sequences encoding the HA1 subunit were 
subjected to cluster analysis of maximum-likelihood 
phylogenetic trees using BioNumerics 7.5 software. 
Furthermore, encoded HA1 subunit sequences were 
checked for match to the signature amino acid substi-
tutions of the genetic categories that individual viruses 
had been ascribed to. The resulting phylogenetic trees 
were checked for misattributed viruses, as well as for 
apparent clade patterns beyond the resolution of the 
categories provided in the TESSy reporting scheme. 
The European Reference Laboratory Network for Human 
Influenza (ERLI-Net) reference HA1 encoding sequence 
sets provided by WHO CC for the 2013/14 season were 
used as reference sequences in the analysis. To better 
understand the ongoing evolution of the viruses and in 
order to check for the presence of groups that predomi-
nated in the following season, two A(H3N2) and one B/
Yamagata-lineage ERLI-Net reference viruses defined 
for the subsequent 2014/15 season were also included: 
A/Switzerland/9715293/2013(H3N2) (group 3C.3a); A/
Hong Kong/5738/2014(H3N2) (group 3C.2a); and B/
Phuket/3373/2013 (clade 3).
Extended virus characterisation was achieved by 
including antiviral susceptibility data in the analysis. 
To standardise interpretation and reporting of influ-
enza virus susceptibility to the neuraminidase (NA) 
inhibitors (NAIs) oseltamivir and zanamivir, WHO-
Antiviral Working Group definitions, based on half 
maximal inhibitory concentration (IC50),were used [15]. 
Raw IC50 data were converted into relative fold-change 
values compared with the median of all data by virus 
type or subtype and NAI to facilitate pooled analysis 
of the data from all laboratories [16]. As influenza B 
virus IC50 data varied widely between laboratories, the 
fold-changes for influenza B viruses were calculated by 
reporting laboratory. IC50 fold-change data were gen-
erated to classify the viruses as with normal inhibition 
(NI), reduced inhibition (RI) or highly reduced inhibi-
tion (HRI). Amino acid substitution data were analysed 
against published data on specific amino acid substi-
tution in the M2 and NA proteins previously associated 
with resistance to adamantane M2 ion channel block-
ers and RI or HRI by NAIs (oseltamivir and zanamivir), 
respectively [17].
Patients were stratified into the following age 
groups: < 1 year, 1–5 years, 6–19 years, 20–39 years, 
40–64 years and ≥ 65 years. Distribution of sex by 
age group was tested for significance using the non-
parametric Kruskal-Wallis test. Distribution of genetic 
clades in different age groups was compared by Dunn’s 
test (multiple pairwise comparisons using rank sums) 
with Bonferroni adjustment. The level of significance 
was set at p < 0.05.
Table 1
Strain-based reporting: numbers of influenza viruses by antigenic group and genetic clade, 11 European countries, 
influenza season 2013/14 
Antigenic group Number (%) Genetic clade Number (%)
Number of viruses with 
both antigenic and genetic 
data
A/California/7/2009 (H1N1)pdm09 306 (46) A/St Petersburg/27/2011 (H1N1)pdm09 513 (46) 72
A(H1N1)pdm09 not categorised 0 (0) A(H1N1)pdm09 not categorised 0 (0) 0
A/Texas/50/2012 (H3N2) 305 (46) A/Texas/50/2012 (H3N2) 519 (46) 52




(Victoria-lineage) 13 (1) 4




(Yamagata-lineage) 22 (2) 11
NA NA B/Wisconsin/1/2010 (Yamagata-lineage) 50 (4) 0
B (Yamagata-lineage) not categorised 3 (0.5) B (Yamagata-lineage) not categorised 0 (0) 0




Participating countries, data completeness and 
feasibility
Eleven of 30 EU/EEA countries participated in this 
pilot: Belgium, Finland, Germany, Greece, Ireland, Italy, 
the Netherlands, Norway, Portugal, Spain and Sweden. 
However, Belgium did not report patient age and sex, 
so Belgian cases were excluded from epidemiological 
analysis. Data completeness is shown in Table 2. All 
reporting laboratories found the reporting feasible and 
recommended the use of it to other laboratories in the 
questionnaire (data not shown).
Participating countries detected 15,669 influenza 
viruses during the 2013/14 season of which 3,920 (25%) 
were from sentinel and 11,749 (75%) from non-senti-
nel sources (Table 3). The same countries submitted 
strain-based data for 1,633 influenza viruses (10% of 
the detections): 586 (36%) were from sentinel sources 
and 1,037 (64%) from non-sentinel sources (Table 3). 
For 10 viruses (1%), the source was not declared.
In both sentinel and non-sentinel specimens, influenza 
types A and B were detected and all type A viruses 
were subtyped. Participating countries detected 9,779 
(62%) A(H1N1)pdm09, 4,933 (32%) A(H3N2) and 957 
(6%) type B viruses. Of the B viruses, lineage was 
determined for 234 (24%), and of these, 218 (93%) 
were B/Yamagata-lineage (Table 3).
Of the 1,633 viruses reported in the strain-based sys-
tem, 747 (46%) were A(H1N1)pdm09, 779 (48%) A(H3N2) 
and 107 (7%) type B viruses (Table 3). A slightly higher 
proportion of viruses were characterised from sentinel 
than from non-sentinel sources (Table 3).
Of the 1,633 viruses characterised, 516 (32%) were only 
characterised antigenically, 974 (60%) only geneti-
cally and 143 (9%) both antigenically and genetically 
(Table 1). For the latter, the antigenic and genetic char-
acterisation data were consistent. The participating 
countries contributed unequally to the antigenic and 
genetic characterisation data. Germany submitted 300 
(45%) and Portugal 151 (23%) of the 659 antigenic char-
acterisation records, with other countries contributing 
between one (0.2%) and 58 (9%) of the records while 
Finland and Sweden submitted no antigenic data. 
Spain contributed the most genetic characterisation 
data, accounting for 513 (46%) of the 1,117 records, 
with other countries providing details on between 10 
(1%) and 125 (11%) viruses. Italy provided no genetic 
characterisation data.
Antigenically and genetically characterised viruses 
fell mainly in the A/California/7/2009 (H1N1)pdm09-
like (in the A/St Petersburg/27/2011 subgroup) and A/
Texas/50/2012(H3N2)-like reporting categories (46% in 
each category), the A(H1N1) and A(H3N2) components 
of the 2013/14 northern hemisphere influenza vac-
cines. Eleven A(H3N2) viruses were reported as ‘not 
categorised’ antigenically and would therefore be low 
reactors or not reacting with antiserum against the ref-
erence virus. For four of these, the genetic category was 
assigned as A/Texas/50/2012(H3N2). For the remaining 
seven viruses, no additional genetic information was 
available.
Type B viruses were detected in smaller num-
bers than influenza A viruses, and only 37 type 
B viruses were characterised antigenically: 11 B/
Victoria-lineage viruses as B/Brisbane/60/2008-
like and 26 B/Yamagata-lineage viruses as B/
Massachusetts/02/2012-like (n = 23; 2013/14 vaccine 
component) or as ‘not categorised’ (n = 3), respectively. 
Of the 85 B viruses characterised genetically, 13 were 
B/Victoria-lineage viruses, and of the 72 B/Yamagata-
lineage viruses, 22 and 50 fell within clades repre-
sented by B/Massachusetts/02/2012 (clade 2) and B/
Wisconsin/1/2010 (clade 3), respectively.
To analyse the distribution of characterisations over 
the influenza season, we compared the number of char-
acterisations and detections by weeks. The influenza 
season in the 11 participating countries occurred from 
week 49/2013 to week 18/2014. The highest numbers 
of detections of A(H1N1)pdm09 viruses were reported 
in week 04/2014 for sentinel sources and week 
06/2014 for non-sentinel sources. A(H3N2) virus detec-
tions peaked in week 04/2014 for sentinel and week 
08/2014 for non-sentinel sources (Figure 1). Although 
B viruses were detected throughout the season, detec-
tions peaked in week 15/2014, originating mostly from 
non-sentinel sources (data not shown).
For A(H1N1)pdm09 viruses, similar reporting patterns 
were seen for both phenotypically and genetically 
characterised strains, with the majority being reported 
in weeks 01–11/2014. Similarly, for A(H3N2) viruses, 
the majority of strain-based reports were for viruses 
detected in weeks 02–12/2014. Although low, the high-
est numbers of influenza B detections occurred during 
weeks 04–21/2014. Antigenic characterisations of B 
viruses were reported for weeks 40/2013–20/2014 and 
genetic characterisations for weeks 40/2013–27/2014 
(data not shown). Overall, the number of antigenic and 
genetic characterisations followed the season progres-
sion for all virus (sub)types.
All 596 HA sequences (271 H1, 287 H3, 7 B/Victoria 
and 31 B/Yamagata), for which accession numbers 
had been provided in TESSy, were retrieved. Analysis 
of genetic group-defining amino acid substitutions 
and phylogenetic clades revealed that all sequences 
available for this analysis were categorised in accord-
ance with the reporting scheme. However, a number 
of sequences (71 A(H1N1)pdm09, 54 A(H3N2) and 6 B/
Yamagata) were excluded from the phylogenetic analy-
sis because they did not cover either full-length coding 
regions of HA1 subunit for influenza A(H1) and (H3), or 
HA1 amino acids 28–314 for type B/Victoria or 22–339 
for type B/Yamagata.
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For A(H1N1)pdm09 viruses, all 271 sequences analysed 
were correctly attributed to the broad genetic group 
represented by A/St.Petersburg/27/2011, known as 
group 6 in global influenza surveillance terminology. 
No further distinction was available in the reporting 
scheme. However, all viruses belonged to subgroup 
6B, represented by reference viruses such as A/South 
Africa/3626/2013 and A/Norway/2417/2013 (Figure 
2A).
All A(H3N2) viruses were reported as belonging to the 
group represented by A/Texas/50/2012 (the 2013/14 
vaccine virus), a subgroup 3C virus subsequently 
defined as representing the 3C.1 subdivision after the 
2013/14 influenza season. Amino-acid signature and 
phylogenetic cluster analysis confirmed that all avail-
able sequences were correctly attributed to subgroup 
3C, but distributed within two subdivisions, 3C.2 and 
3C.3. One virus (A/Norway/466/2014) clustered with 
the antigenic drift variant A/Switzerland/9715293/2013 
which was representative of genetic subgroup 3C.3a 
viruses and is the recommended A(H3N2) vaccine 
virus for the 2015/16 influenza season (Figure 2B). No 
sequences clustered with another genetic subgroup, 
3C.2a, associated with antigenic drift in the course of 
the subsequent 2014/15 influenza season.
B/Yamagata-lineage viruses fell within the two circulat-
ing clades represented by B/Massachusetts/02/2012 
(clade 2; vaccine virus 2013/14) and B/
Wisconsin/01/2010 (clade 3). The majority was 
attributed to clade 3. Consistent with this, avail-
able sequences clustered with these two groups and 
were in all instances correctly attributed (Figure 2C). 
Notably, the majority of clade 3 sequences closely 
matched a recent reference virus, B/Phuket/3073/2013, 
recommended for use in southern hemisphere 2015 
and northern hemisphere 2015/16 influenza vaccines. 
All seven B/Victoria-lineage sequences clustered with 
the clade 1A reference sequences of which the vaccine 
virus, B/Brisbane/60/2008, is representative (Figure 
2D)
Of the 1,633 viruses with antigenic and/or genetic 
characterisation data, 678 (42%) were tested for neu-
raminidase inhibitor (NAI) susceptibility using genetic 
and/or phenotypic methods: 349 A(H1N1)pdm09, 264 
A(H3N2), 54 B/Yamagata-lineage and 11 B/Victoria-
lineage viruses. One A(H1N1)pdm09 virus carrying 
neuraminidase (NA) I223R amino acid substitution 
showed reduced inhibition (RI) by oseltamivir. Two 
others showed RI by zanamivir, only one of which was 
sequenced and shown to carry NA S247I substitution. 
One virus carried NA H275Y substitution which has 
been associated with highly reduced inhibition (HRI) 
by oseltamivir but it was not tested phenotypically. 
One A(H3N2) virus showed RI by oseltamivir and zan-
amivir and one by zanamivir only. Both viruses were 
sequenced but no amino acid substitutions previously 
or potentially associated with RI were identified. One B 
virus showed RI by zanamivir (sevenfold) but no amino 
acid substitution previously or potentially associated 
with RI was identified. For 80 cases with antiviral sus-
ceptibility data, antiviral treatment with oseltamivir up 
to 14 days before specimen collection was reported, 
including one case infected with an A(H3N2) virus 
showing RI by zanamivir. All other cases with indica-
tions of being infected with viruses showing RI or 
HRI by a NAI, for which antiviral exposure status was 
reported, had not received antivirals before specimen 
collection. One case infected with A(H1N1)pdm09 car-
rying NA S247N substitution was exposed to oseltami-
vir through a treated household contact.
Sex and age
The majority of the 1,547 cases for which age was 
reported by 11 countries were adults aged 20–64 
years (53%). The sex distribution did not vary signifi-
cantly across age groups (50% female and male, n = 
1,535; p = 0.1611). Age and genetic clade was avail-
able for 1,061 cases. A/St Petersburg/27/2011-like 
A(H1N)pdm09 viruses affected age groups < 1 year, 
20–39 years and 40–64 years (65%, p = 0.0111; 50%, 
p = 0.0046; 55%, p = 0.00001, respectively) more than 
the  ≥ 65 years age group (34%). A/Texas/50/2012-like 
A(H3N2) viruses affected more of the  ≥ 65 year olds 
(62%; p = 0.0012) than 20–39 year olds (44%). A/
Texas/50/2012-like A(H3N2) viruses affected the age 
groups < 1 year (26%; p = 0.0014) and 40–64 years 
(35%; p = 0.00001) less than the age group ≥ 65 years 
(Figure 3A).
Hospitalisation status and influenza virus subtype 
were reported for 1,147 (70%) of 1,633 cases. Of these, 
672 cases were reported from non-sentinel sources 
and included reporting from 10 countries (Finland, 
Germany, Greece, Ireland, Italy, the Netherlands, 
Table 2
Data completeness for reported variables, strain-based 
reporting of antigenic and genetic characterisation data 
for influenza viruses, 11 European countries, influenza 
season 2013/14 (n=1,633)
Variable Number (%)
Virus (sub)type 1,633 (100)
Sex 1,577 (97)
Age 1,547 (95)
Hospitalisation status 1,147 (70)
Date of onset 1,052 (64)
Vaccination status 798 (49)
Patient given or not given antivirals before 
collection of specimen 725 (44)
Probable country of infection 669 (41)
Immunocompromised status 521 (32)
Outcome (alive/dead) 521 (32)
Complication diagnosis 219 (13)
Household member given or not given 
antivirals before collection of specimen 75 (5)
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Norway, Portugal, Spain and Sweden). Patient age 
and virus subtype/genetic clade information were 
available for 325 hospitalised patients from Finland, 
Greece, Ireland, the Netherlands, Norway, Portugal, 
Spain and Sweden (Figure 3B). Influenza subtypes 
and genetic clades associated with hospitalisation dif-
fered between age groups. Hospitalised cases in the 
6–19 years age group and ≥ 65 years of age were most 
frequently infected by A/Texas/50/2012-like A(H3N2) 
viruses, 8/12 (67%; p = 0.0494) and 58/111 (52%; 
p = 0.0005), respectively (Figure 3B). All other hospital-
ised cases were infected in higher proportions by A/
St Petersburg/27/2011-like (H1N1)pdm09 viruses, with 
rates of infection in children 6–19 (p = 0.0306) and 
adults ≥ 65 (p = 0.0011) years of age being significantly 
less than in 40–64 year olds.
Outcome
Among 521 of 1,633 cases with known disease outcome 
(alive/dead) from six countries (Greece, Ireland, Italy, 
Norway, Portugal and Spain), 41/521 (8%) died: 34/266 
(13%) with A(H1N1)pdm09, 7/227 (3%) with A(H3N2) 
and 0/28 cases with type B influenza. Overall, A(H1N1)
pdm09 infection occurred in 34 of 41 fatal cases. The 
majority of fatal cases were middle-aged and elderly 
adults: 20 were ≥ 65 years old and 12 were between 
40 and 64 years old. One infant aged < 1 year (A(H1N1)
pdm09 infected) and two children in the 6–19 age 
group (A(H3N2) infected) died. No further information 
was available for these patients.
Vaccination status
Vaccination status was known for 798 of the 1,633 
cases from all 11 countries; 130 (16%) had been vac-
cinated with the influenza vaccine for the 2013/14 
influenza season. Among these, there were 400 (50%) 
males and 396 (50%) females (two cases with unknown 
sex). Vaccination coverage ranged from 4% in children 
1–5 years of age to 45% among those ≥ 65 years of age. 
None of the infants < 1 year of age had been vaccinated. 
Vaccination status and hospitalisation was known for 
712 patients. Among 139 hospitalised cases, 34 (24%) 
had been vaccinated against influenza. Of those vac-
cinated and hospitalised, 20 had an A(H3N2), 12 an 
A(H1N1)pdm09 and two a B/Yamagata infection. Of the 
16 fatal cases for which vaccination status was known, 
three had been known to be vaccinated. Two of these 
cases were infected by A(H3N2) and one by A(H1N1)
pmd09 virus. Due to limited data completeness for 
outcome and vaccination status, no statistical analysis 
was performed.
Other epidemiological variables
Exposure to antiviral drugs was reported as known for 
725 of 1,633 cases, and of these 576 (79%) had not 
been treated with antiviral drug. Of the cases reported, 
492 of 521 (94%) were not immunocompromised and 
29 had an underlying disease. The probable country of 
infection varied among the cases. For 669 (41%) cases 
this information was entered and 15 (2%) of the cases 
had probably acquired their infection during travel 
outside Europe (in Aruba, China, Indonesia, Israel and 
Saudi Arabia).
Discussion
In this pilot study, TESSy was used to capture influenza 
virus strain-based antigenic and genetic characterisa-
tion data allowing phylogenetic analysis and reporting 
on the demographic information, outcome, vaccina-
tion status, immune status and the probable country 
Table 3






Characterised viruses as a 
proportion of detections (%)
Sentinel Non-sentinel Total Sentinel
Non-
sentinel Unknown Total Sentinel
Non-
sentinel Total
A(H1N1)pdm09 2,089 7,690 9,779 237 505 5 747 11.3 7 8 
A(H3N2) 1,714 3,219 4,933 311 464 4 779 18.1 14 16 
B(lineage not 
determined) 60 663 723 0 0 0 0 NA NA NA 
B(Victoria) 7 9 16 9 11 0 20 129a 122a 125a 









11,631 112,571 124,202 NAb
NA: not applicable.
a > 100% as some of the B(lineage not determined) viruses were characterised at later dates and then reported by influenza B virus lineage.
b This category is not applicable to strain-based reporting as only influenza-positive specimens can be reported on; the number of ‘specimens’ 
is the total number of reports.
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of origin of the characterised viruses at the European 
level for the first time. Strain-based data analysis 
was feasible based on good data completeness for 
variables such as virus subtype, patient age and sex. 
Large and small countries from northern, southern and 
western parts of EU/EEA reported data and the target 
set for detailed characterisation of 10% of the viruses 
detected was achieved.
Although the distribution of (sub)types in our study 
was not exactly the same as the distribution in all EU/
EEA countries [18], all (sub)types were covered both in 
our aggregate and strain-based data. We recognised 
from past years’ data that the proportions of different 
virus types/subtypes/lineages as well as the dominant 
type/subtype/lineage can vary between countries each 
season.
This pilot study showed that characterised viruses 
were congruent with guidance on targeted sampling 
for further characterisation: the data reported covered 
all age groups and had no sex bias. However, in our 
data, A(H3N2) viruses were slightly overrepresented 
among those selected for characterisation (16% vs 
10% for all subtypes). A(H3N2) viruses have proved 
difficult to characterise antigenically in recent years 
[19] and therefore greater effort has been put into their 
characterisation.
In this pilot study, influenza virus types and subtypes 
did not affect the sexes differently, but did differ across 
age groups: A(H1N1)pdm09 viruses predominated in 
younger adults in the 20–64 years of age group as dur-
ing the 2009 pandemic and in infants <  1 year, while 
A(H3N2) viruses predominated in patients aged ≥ 65 
years, school-aged children and teenagers. Although 
vaccination status was reported, completeness was 
low for underlying diasease and immune status, and 
therefore no conclusions could be drawn on a possible 
effect of vaccination on the age distribution.
It will be of interest to follow the trend for age distri-
bution among hospitalised cases over several seasons 
to better understand the age-distribution of influenza 
infection associated with severe infection by (sub)
types and strains. For the 2012/13 season when type 
B viruses predominated across 12 European countries 
(partly overlapping with this study), children 5–14 
years of age were mostly infected by B viruses while all 
other age groups showed an even distribution of influ-
enza A and B viruses [7].
Phylogenetic analysis was performed to understand 
the evolution of the different sub(types) and lineages 
in comparison to the vaccine strains and over the sea-
son. Overall, in the 2013/14 season, the genetic varia-
tion of circulating viruses was limited and most of the 
viruses belonged to the same genetic category, and 
were closely related to each other, in their respective 
subtype/lineage. All A(H1N1)pdm09 viruses clustered 
in genetic subgroup 6B that contains viruses which we 
showed to remain antigenically similar to the vaccine 
virus A/California/7/2009 [20]. The A(H3N2) viruses 
have drifted through several influenza seasons and the 
study population confirmed that the viruses circulating 
in 2013/14 were closely related to the 2013/14 vaccine 
virus, A/Texas/50/2012, within genetic group 3C.1 but 
further evolution was seen by subdivision of viruses 
to 3C.2 and 3C.3 clusters. Interestingly, among the 
2013/14 season H3 sequences studied here, there were 
no sequences already falling in the genetic 3C.2a subdi-
vision which was associated with antigenic drift in the 
course of the 2014 southern hemisphere and 2014/15 
northern hemisphere influenza seasons. Phylogenetic 
analysis of the B/Yamagata viruses confirmed likewise 
the clustering to two groups represented by the 2013/14 
vaccine virus (B/Massachusetts/02/2012; clade 2) and 
the 2015/16 vaccine virus (B/Phuket/3073/2013; clade 
3). The circulating B/Victoria viruses remained closely 
related to the B/Brisbane/60/2008 vaccine virus.
In this pilot study, 34/41 of fatal cases were related to 
A(H1N1)pdm09 infection, compared with 58% in eight 
countries reporting outcomes through hospital surveil-
lance in 2013/14 [21]. In the hospital surveillance data, 
many of the influenza viruses are reported without sub-
type and therefore no exact comparison is possible. 
Overall, only 41 (3%) of the 1,633 viruses characterised 
were from fatal cases which does not show a bias of 
the data towards fatal case specimens being character-
ised. An earlier analysis of the 2013/14 season showed 
that fatal outcomes occured mostly in adults > 40 years 
of age [21]; this pilot study showed the highest num-
ber of deaths in those ≥ 65 years of age. Based on our 
limited data on severe infection, hospitalised cases 
affected by A(H3N2) virus infection were mostly school-
aged children and the elderly, in line with the results of 
the meta-analysis for seasonal influenza [11].
Limitations of this study were that: only 11 of the 30 
EU/EEA countries agreed to participate, and only three 
submitted data with indication of hospitalisation sta-
tus with both non-hospitalised and hospitalised cases 
as most laboratories do not have the clinical infor-
mation; and NICs aim for good representativeness of 
specimen selection but acknowledge selection biases 
and constraints in terms of: (i) characterisation of more 
A(H3N2) viruses as these viruses are currently drifting 
rapidly and have become more difficult to culture and 
characterise than A(H1N1)pdm09 viruses; (ii) capturing 
enough type B viruses to inform vaccine composition 
recommendations; (iii) increased interest in hospital-
ised and severe cases/deaths; (iv) limited resources 
and therefore focus on start, middle and end of sea-
son; (v) influenza surveillance systems may underes-
timate the cases in both ends of the age span due to 
healthcare seeking behaviour and sampling at outpa-
tient clinics.
The extension of the existing antiviral strain-based 
reporting scheme with genetic and antigenic character-
isation data was welcomed and supported by the pilot 
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countries and it strengthens EISN as virological data 
reported can be subjected to more detailed analysis 
inclusive of the associated demographic and clinical 
information. We consider this as a substantial improve-
ment over the previous aggregate reporting of antigenic 
and genetic categories only. Strain-based reporting 
also enabled early 2014/15 and 2015/16 influenza sea-
son analysis including HA phylogeny [22,23]. Through 
more traditional hospital surveillance, only virus sub-
type information related to hospitalisation has been 
reported by eight countries [24], but now genetic clade 
can be associated with information on hospitalisation.
We recommend the strain-based reporting to all EISN 
laboratories and we also recommend that laborato-
ries continue to select specimens for characterisation 
across subtypes, geographic location and age groups, 
related to indicators of clinical status. The same prin-
ciples as for selecting specimens to be sent to WHO 
CCs for detailed characterisation and informing vac-
cine composition recommendations may be adopted 
for national specimen selection [14]. Further, detailed 
reporting may allow greater definition of risk groups 
and support targeted vaccination and antiviral treat-
ment strategies, e.g. if data on underlying conditions 
are included. The data should be combined with avail-
able hospital surveillance data as they may provide 
new ways of looking into vaccine effectiveness that 
has been low for A(H3N2) viruses in recent years [25].
The interplay between clinicians, epidemiologists and 
virologists collecting this type of data with public 
health specialists is crucial to ensure an even more 
representative sampling scheme for virus specimens. 
This will help to provide data for better estimates of 
risk factors associated with influenza.
* Authors’ correction
The percentage marked with an asterisk was corrected, to 
62%, at the request of the authors on 13 October 2016.
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